August 10, 2023

National Stock Exchange of India Limited, BSE Limited,

Compliance Department, Compliance Department,
Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers,
Bandra (East), Mumbai - 400051, Dalal Street, Mumbai - 400001,
Maharashtra, India Maharashtra, India

Dear Sir/Madam,

Subject : Investor Presentation

Stock Code : BSE – 539787, NSE – HCG

Reference : Regulation 30 read with Schedule III of SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”)

We wish to inform you that the Board of Directors of the Company, at their meeting held on
August 10, 2023, inter alia, has approved the Unaudited Financial Results (Standalone and
Consolidated) of the Company for the quarter ended June 30, 2023 (“Financial Results”).

In this respect, we enclose herewith the Presentation on the Financial Results of the Company
for the quarter ended June 30, 2023.

Request you to take this on record.

Thanking you,

For HealthCare Global Enterprises Limited

SUNU Digitally signed by
SUNU MANUEL ABEY
MANUEL Date: 2023.08.10
ABEY 21:21:08 +05'30'

Sunu Manuel
Company Secretary & Compliance Officer

Encl: a/a.

HealthCare Global Enterprises Limited

HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027.
080 33669999 | [email protected] | www.hcgoncology.com | CIN : L15200KA1998PLC023489
HEALTHCARE GLOBAL ENTERPRISES LIMITED

I NV ESTOR P R ESENTATI ON
August 2023
 SAFE HARBOR
This presentation and its contents are confidential and are not for release, publication or distribution, in whole or in part, directly or indirectly, in or into or from the United States of America, Canada,
Australia, Japan or any jurisdiction where such distribution is unlawful.

This presentation has been prepared by HealthCare Global Enterprises Limited (the "Company") . These materials are not for publication or distribution, directly or indirectly, in or into the United States
(including its territories and possessions, any state of the United States and the District of Columbia). These materials are not an offer of securities for sale into the United States, Canada or Japan or any
other jurisdiction. Any securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States, except
pursuant to an applicable exemption from registration. No public offering of any securities of the Company is being made in the United States.

The information contained in this presentation is for information purposes only and does not constitute or form part of an offer or invitation for sale or subscription of or solicitation or invitation of any offer
to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract, commitment or investment decision in relation thereto in India, the United
States or any other jurisdiction.

No person accepts any liability whatsoever for any loss howsoever arising from the use of this document or of its contents or otherwise arising in connection therewith. The information set out herein may be
subject to updating, completion, revision, verification and amendment without notice and such information may change materially. Financial information contained in this presentation has been derived from
the restated consolidated and standalone financial statements of the Company and have been rounded off to the next integer, except percentages which have been rounded off to one decimal point.

This presentation contains certain "forward looking statements". Forward‐looking statements are based on certain assumptions and expectations of future events. Actual future performance, outcomes and
results may differ materially from those expressed in forward‐looking statements as a result of a number of risks, uncertainties and assumptions . Although the Company believes that such forward‐looking
statements are based on reasonable assumptions, it can give no assurance that such expectations will be met. Neither the Company nor any of its advisors or representatives assumes any responsibility to
update forward-looking statements or to adapt them to future events or developments .

This presentation includes certain industry data and projections that have been obtained from industry publications and surveys. Industry publications and surveys and forecasts generally state that the
information contained ther ein has been obtained from sources believed to be reliable, but there is no assurance that the information is accurate or complete. Neither the Company nor any of its advisors or
representatives have independently verified any of the data from third-party sources or ascertained the underlying economic assumptions relied upon therein. No representation or claim is made that the
results or projections contained in this presentation will actually be achieved. All industry data and projections contained in this presentation are based on data obtained from the sources cited and involve
significant elements of subjective judgment and analysis, which may or may not be correct. For the reasons mentioned above, you should not rely in any way on any of the projections contained in this
presentation for any purpose. No responsibility or liability whatsoever is undertaken for the contents hereof.

This presentation is based on information regarding the Company and the economic, regulatory, market and other conditions as in effect on the date hereof . It should be understood that subsequent
developments may affect the information contained in this presentation, which neither the Company nor its advisors or representatives are under an obligation to update, revise or affirm.

2
www. h c g e l . c o m
 Q1FY24 FINANCIAL &
SUBASENI LENKA, CANCER WINNER OPERATIONAL HIGHLIGHTS
I am eternally thankful to
Dr. Panda and other specialists at
HCG Panda Cancer Hospital, as
the specialists were able to treat
my condition the right way, the
first time

3
www. h c g e l . c o m
Acquisition 1: HCG NCHRI, Nagpur

About HCG NCHRI

❖ HCG NCHRI LLP operates and manages 115 bedded hospital in Nagpur, providing
comprehensive cancer care services under medical services agreement
❖ Revenue from operations of HCG NCHRI LLP for the financial year ended March 31, 2023, was
INR 51.4 Crores

ABOUT THE TRANSACTION

❖ The company entered into Share Purchase agreement with shareholders of NCHRI; Dr Ajay
Mehta & Dr Suchitra Mehta for acquisition of Shares in NCHRI
❖ The company also entered into Partnership Transfer Agreement with Dr Ajay Mehta in HCG
NCHRI Oncology LLP to acquire his partnership interest

With this acquisition of NCHRI and HCG NCHRI LLP, the Company can entirely consolidate the
business operations in Nagpur, and this would result in a better financial and operating
structure

4
www. h c g e l . c o m
 Acquisition 2: SRJ CBCC Hospital, Indore
Asset Overview
• Indore based Comprehensive Cancer Care (CCC) hospital
• 50 beds facility offering Medical, Surgical and Radiation oncology
• First & #1 Comprehensive Cancer Center in private space in Indore
• To acquire 100% of hospital on a slump sale basis

Strategic Rationale
• New Market Entry: Entering a key non-metro city with a quality asset & HCG
brand
• Attractive market dynamics: Suitable market dynamics with no large non -
charitable hospital present for Oncology
• Attractive market: Oncology market estimated to grow at 15-20% CAGR
• Capacity Expansion: Capacity expansion by 100 beds at a nearby location,
estimated to be operational in 2 years

Financials • Potential levers for increasing scale: Launch of Organ specific practice, LINAC
addition, serving new patient channels
• Potential levers to improve margins: Operational efficiencies & Synergies
Particulars FY20 FY21 FY22 FY23E

Revenue (Rs. in
244 286 321 325
Mn)

5
www. h c g e l . c o m
 Le v e r aging a s uc c essf u l p la y b ook of s ma r t a c q u is it ions a nd d r iv ing
s u s t a ine d gr ow t h p os t a c q u is it ion

Time tested and highly replicable model of consistent revenue growth across geographies

HCG Ahmedabad HCG Cuttack HCG Vijayawada HCG Nashik

Acquisition 2013(1) 2008 2018 2016
Year
• Primarily surgical oncology • Primarily surgical oncology • 20%+ EBITDA margins • #1 player in market
Situation at • Outside of Top 3 position • Single doctor dependent • #1 player in market • Primarily surgical oncology
acquisition • Single digit EBITDA margin • Single digit EBITDA margin • Primarily surgical oncology • High doctor concentration
• Single doctor dependent

• Comprehensive cancer care • Comprehensive cancer care

• #1 player in market • #1 player in market • Strengthened radiation and
• Reduced doctor
• Strong multi-modal clinical • Comprehensive cancer care medical oncology clinical
concentration
practice • Deployed latest technology talent
Outcome • Investment in latest
• Built a CoE far patient care • Diversified doctor revenue
technology and clinical
• 25%+ EBITDA margin • 25%+ EBITDA margin mix
expertise
• 3x capacity addition
6
(1) HMS (multispecialty) was acquired in 2007 but the comprehensive cancer care unit – HCC was demerged in 2013
www. h c g e l . c o m
 Clinical Highlights & Recognitions
Noteworthy Clinical Achievements
❖ Dr Joydeep Chakrabartty, Senior Consultant, BMT & Haematology, HCG Kolkata was
selected as the Country Advisor for East India by the Royal College of Pathologists

❖ Dr Nishit Ojha, Dr Amey Panchal (Fellows in BMT & Haematology) & Dr Sachin Jadhav,
Director, BMT & Haematology identified a new mutation "Whole transcriptome sequencing
reveals HOXD11-AGAP3, a novel fusion transcript in the Indian acute leukemia cohort”

❖ Dr. Vishal U S Rao & Swetha Kannan were awarded the prestigious Lee Yung grant from
Trinity Hall, University of Cambridge to support the development of a novel spectroscopy-
based tool for early-detection of cancers in India. Their preliminary research is published in
the journal’ Medical Hypothesis

Research and Academics:

❖ Total No of students ~290
❖ Total Courses 44
❖ Total allied health programs ~4
❖ Total Nursing Programs is 5
❖ Total DNB Programs is 7
❖ Total DNB students is 70
❖ Total Fellowship Programs is 26

7
www. h c g e l . c o m
 Financial Highlights Q1 FY24
REVENUE R E V E N U E - H C G C e n t e r s (1) REVENUE - Milann Centers

+13% +14% -5%

4,607 4,443 173 164
4,081 3,908

Q1FY23 Q1FY24 Q1 FY23 Q1 FY24 Q1FY23 Q1FY24

PROFIT AFTER TAX PROFIT AFTER TAX

EBITDA* EBITDA* MARGIN
(Pre-IND AS) (Post-IND AS)
# Proforma

+5% EBIDTA - 117 bps +17% +25%

764 801 17.8% 16.6% 110 76

725 94 61

Q1FY23 Q1FY24 Q1FY24# Q1FY23 Q1FY24 Q1FY23 Q1FY24 Q1FY23 Q1FY24

*EBIDTA excludes ESOP

#Proforma EBIDTA had these acquisitions would have been done in Q1FY24
8
1. 22 comprehensive cancer centers, 3 multispecialty hospitals Rs in M n www. h c g e l . c o m
Improved Performance Leading to Profitability
2.2x

4081 4200 4247 4417.1 4,607

3231 3520 3581 3646
Revenue 2479 2740 2981
(INR mn) 1935

Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24

3.8x

EBITDA (Excl. 306 744 760 773 778 764

200 632 636 652
ESOP) 488
383 396
(INR mn)
Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24

+ve

PAT (223) (458) 60 61 74 75 84 76

(398) (292) 1,031
(INR mn)
(Post IND-AS (1,022) (96)
116) (1) (2)
Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24

+ve

PAT (158) (60) 94 92 105 111 112 110

(333) (229) 1,067 (424)
(INR mn) (958)
(Pre IND-AS
116) (1) (2)
Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24

9
(1) Includes loss due to exceptional items of INR 847 mn
www. h c g e l . c o m
(2) Includes gain on exceptional items of INR 1,401 mn
 Growth Across HCG Centers*
Matured Centers Emerging Centers^

~1.4x g r o w t h i n l a s t 9 q u a r t e r s ~1.7x g r o w t h i n l a s t 9 q u a r t e r s
+11% +22%
REVENUE#

3,169 3,314 1,090 1,129

2,979 3,090 3,065 1,015
2,596 2,628 2,663 929 945
2,418 785 826
693 750

Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q1FY24

Matured Centers Emerging Centers^

~1.3x g r o w t h i n l a s t 9 q u a r t e r s ~12.5x growth in last 9 quarters

+2%
-8%
E B I T DA * *

744 775 786 777 761 108

682 99 99
645 658
606 81
75 76

33 36

Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q1FY24
**Excl. Corporate Expenses, Numbers restated due to lab vertical allocation correction - from Q3'22
10
^Emerging Center represents centers operational after 2017 * Excl . Revenue & EBIDTA for Fertility www. h c g e l . c o m
 Strong Operating Metrics with Significant Capacity Headroom

Key Driver Metric Indicator % Revenue Q1’23 Q4’23 Q1’24

14%

92 95 105
Lead indicator of Volume Growth; key
OPD Footfall (‘000) operating metric tracked by HCG; has 19%*
correlation to OPD Footfalls

9%

32 34 35
Key indicator for Medical Oncology;
Chemo Sessions 42%
procedures are primarily day care oriented
Administered (‘000) with no capacity constraint

67% 65% 69%

Key indicator for Radiation Oncology;
LINAC - Capacity availability of LINACs is the only capacity
Utilization constraint; further augmenting capacity by 17%
20%

Indicator for Surgical Oncology; with 65% 63% 66%

decreasing ALOS and flexibility to add balance
Onco-Bed#
Occupancy
non-operational capacity beds, not a capacity 21%
constraint operationally; additional 195 beds
available to be made operational
11
*Revenue % for out-patient and others only;
# Onco-bed occupancy is for 1,372 beds (1,177 operational beds), including daycare www. h c g e l . c o m
 HCG – Q1FY24 Operational Metrics #
MATURED CENTERS EMERGING CENTERS MATURED CENTERS
TOTAL AOR (%)
AOR (%) A O R ^* ( % ) ROCE (%)

66.9% 67.1% 66.4% 20.2%

61.0% in Q1FY23 61.7% in Q1FY23 59.4% in Q1FY23 19% in Q1FY23

590 bps 540 bps 700 bps 120 bps

ROCE pre-corporate
a l l o ca t i o n s s ta n d s a t 2 4 . 5 %

MATURED CENTERS EMERGING CENTERS EMERGING CENTERS^

TOTAL ARPOB (Rs.)
ARPOB (Rs.) ARPOB^ (Rs.) ROCE (%)

39,686 41,253 35,766 -5.0%

38,296 in Q1FY23 40,374 in Q1FY23 32,968 in Q1FY23 -4.6% in Q1FY23

3.6% 2.2% 8.5% 40 bps

ROCE pre-corporate
^New Center represents centers operational after 2017
*77% of the capacity beds are operational; AOR 52% on capacity beds
a l l o ca t i o n s s ta n d s a t - 2 . 0 %
#Excl. Fertility
12
Existing Centers Operational beds: 1315 + New Centers Operational Beds: 532 = Total 1,847 Operational Beds
ROCE is annualized for Q1FY24 & Q1FY23
www. h c g e l . c o m
 HCG – Cluster Wise Revenue Break Up #

C LU ST E R Q1FY24 Q1FY23 Y-o-Y Q4FY23 Q-o-Q

K A R N ATA K A 1,504 1,373 10% 1,498 -

G U J A R AT 1,136 1,001 14% 1,084 5%

MAHARASHTRA 659 600 10% 627 5%

EAST INDIA 487 387 26% 479 2%

ANDHRA PRADESH 334 297 13% 289 16%

TA M I L N A D U 76 60 27% 73 4%

NORTH INDIA 213 174 23% 176 21%

AFRICA 33 16 108% 33 -

T O TA L 4,443 3,908 14% 4,259 4%

KOLKATA RAJKOT RANCHI JAIPUR NAGPUR

54% Y-o-Y for 51% Y-o-Y 27% Y-o-Y 22% Y-o-Y 18% Y-o-Y
Q1FY24 For Q1FY24 For Q1FY24 For Q1FY24 For Q1FY24

13
#Excl. Fertility Revenue Rs in M n www. h c g e l . c o m
 Milann – Implementing Strategic Initiatives

BENGALURU (5 Centers)
Growth Growth
Particulars Q1FY24 Q1FY23 Q4FY23
Y-o-Y Q-o-Q

New Registrations 1,212 1,612 -24.8% 1,286 -5.8% M S Ramaiah Nagar

Shivananda
IVF Cycles 414 538 -23.0% 461 -10.2% Indiranagar

Revenues Whitefield
164 173 -5.1% 158 3.8%
(Rs. Mn.) Sarjapur JP Nagar

HSR Emerging Centers

E xp a n ding fo o tp ri nt i n B a n galo re – 2 C e nte rs a d d ed Matured Centers (1)

• Continuous focus on strengthening clinical talent NORTH INDIA (2 Centers)

• N e w i n i t i a t i v e s l i ke M e n ' s h e a l t h & C r y o p r e s e r v a t i o n a n d d e e p e r p e n e t ra t i o n i n
co rp o rate an d fo cu s gro ups

Chandigarh
Fo c u s o n m a rket l e ad ers hip i n B a n galo re
Delhi

14
1. Centers in operation prior to April 1, 2016, i.e., Shivananda, JP Nagar and Indiranagar www. h c g e l . c o m
 Capital Expenditure & Net Debt
CAPITAL EXPENDITURE (Rs. Mn.) NET DEBT (Rs. Mn.)

NET DEBT 30 th June 2023 31 st March 2023

HCG CENTERS Q1FY24 Q1FY23 Bank Debt ( 1) 3,462 3,733
Vendor Finance ( 2) 321 223
Matured Centers 326 122 Other Debt 6 8
Less: Cash & Cash Equivalents ( 3) 1,623 1,983
Emerging Centers 10 41 NET DEBT 2,167 1,980
Capital Leases: Ind AS116 5,191 5,019
TOTAL CAPEX 336 163
Net Debt (Incl. Leases) 7,358 6,999
Addition in debt on account of Acquisition 1,070 -
Capital Leases: Ind AS116 on a/c of acquisition 91
ONGOING CAPEX (Rs. Mn.) Pro-forma Net Debt (incl. Leases) 8,519 6,999

Capex incurred till Expected Capex for Expected date of

Sr. No Particulars Total Planned Capex
30 th June 2023 FY24 Operations

1 Ahmedabad – Phase II 180 628 852 Q1 FY25

Whitefield (Extension of
2 10 150 250 Q3 FY25
Bangalore - COE)
1. Bank debt: Net of Bank balance held as margin money of INR 147 Mn and investment in fixed deposits of INR 11.23 Mn (Margin mo ney value reclassed to other deposit) as of 30th June -23, INR 147 Mn and investment in
fixed deposits of INR 17 Mn as of 31 st Mar -23. The unamortized portion of processing fees amounting to INR 27.99 Mn as on 30th June -23 & INR 29.37 Mn as on 31st Mar -23 netted off against Bank Debt.
2. Vendor Finance; Includes Forex reinstatement of INR (1.35) Mn as of 30th June -23 and Forex reinstatement of INR (1.46) Mn as of 31st Mar-23
3. Cash and cash equivalents: Includes investment in mutual funds of INR 17.5 Mn as at 30 th June -23 and of INR 16 Mn as at 31st Mar -23
15
www. h c g e l . c o m
 Q1 FY24 Consolidated Profit & Loss Account
Profit and Loss (in Rs. Mn.) Q1 FY24 Q1 FY23 Y-o-Y Q4 FY23 Q-o-Q
Revenues from Operations 4,597.1 4,073.1 4,409.8
Income from Govt. Grant 9.7 7.4 7.3
Total Revenue from Operations 4,606.8 4,080.5 12.9% 4,417.1 4.3%
Cost of Goods Sold 1,179.1 978.0 1,164.0
Employee Cost 748.0 668.5 673.6
Medical Consultancy Charges 973.8 866.7 912.9
Other Expenses 941.8 842.4 888.4
EBITDA Excluding ESOPS 764.1 724.9 5.4% 778.2 -1.8%
EBITDA Excluding ESOPS (%) 16.6% 17.8% -117 bps 17.6% -103 bps
ESOP’s 21.0 18.6 15.0
Reported EBIDTA 743.1 706.3 5.2% 763.2 -2.6%
Reported EBITDA Margin (%) 16.1% 17.3% -117 bps 17.3% -114 bps
Depreciation 410.1 396.7 422.0
Other Income 24.2 29.1 46.5
EBIT 357.2 338.7 387.7
Finance Cost 255.5 249.8 256.3
Share in Profit/(loss) in JV and Associates 3.5 0.0 -0.1
Profit before Tax 105.2 104.2 131.3
Taxes, Other Comprehensive Income & Minority Interest 29.1 43.7 47.6
Profit After Tax 76.1 60.5 25.8% 83.7 -9.1%
PAT Margin (%) 1.7% 1.5% 16 bps 1.9% -24 bps
16
www. h c g e l . c o m
 HISTORICAL FINANCIAL
SHANKAR, CANCER WINNER
HIGHLIGHTS
The days I was at HCG,
I felt like I was sleeping at
home. They never stop caring
for you. The doctors and
nurses are always finding ways
to make this difficult journey
as comfortable as possible

17
www. h c g e l . c o m
 Historical Profit & Loss Account
Profit and Loss (in Rs. Mn.) FY23 FY22 FY21 FY20 FY19 CAGR
Revenues from Operations 16,914 13,948 10,092 10,923 9,760
Income from Govt. Grant 30 30 43 33 27
Total Revenue from Operations 16,944 13,978 10,134 10,956 9,787 15%
Costs of Goods Sold 4,241 3,549 3,632 3,645 3,581
Employee Cost 2,687 2,337 1,959 2,080 1,845
Medical Consultancy Charges 3,561 2,958 2,218 2,451 2,114
Other Expenses 3,248 2,754 2,289 2,305 2,389
EBITDA 3,208 2,380 1,266 1,722 1,252 24%
EBITDA Margin (%) 18.9% 17.0% 12.5% 15.7% 12.8%
Depreciation 1,635 1,583 1,592 1,485 851
Other Income 132 127 170 70 74
EBIT 1,484 924 -157 307 475 32%
Finance Cost 1,035 978 1,192 1,377 699
Extraordinary Items - 946 -847 - -
Share in Profit/(loss) in JV and Associates - -14 -4 -123 -110
Profit before Tax 449 878 -2,199 -1,193 -334 NA
Taxes, Other Comprehensive Income & Minority
155 340 -264 -131 -86
Interest
Profit After Tax 293 538 -1,935 -1,062 -248 NA
PAT Margin (%) 1.7% 3.8% -19.1% -9.7% -2.5%
EPS (in INR) 0 4.1 -16.9 -2.9 -2.8

18
www. h c g e l . c o m
 Historical Balance Sheet
Balance Sheet - Equity & Liabilities (in Rs. Mn.) Mar-23 Mar-22 Mar-21 Mar-20 Mar-19
Equity Share Capital 1,391 1,390 1,254 887 879
Other Equity 7,214 7,313 5,718 2,926 3,933
Equity Attributable To Equity Holders Of The Company 8,605 8,703 6,972 3,813 4,811
Non-Controlling Interests 89 134 168 385 619
Total Equity 8,694 8,837 7,140 4,198 5,430
Non-Current Liabilities
Financial Liabilities 0 0 0 0 0
Borrowings 3,628 3,629 3,462 5,296 4,666
Lease Liabilities 4,531 4,659 4,693 6,092 202
Other Financial Liabilities 0 255 0 624 0
Provisions 132 105 86 73 56
Other Non-Current Liabilities 359 0.0 280 422 318
Deferred Tax Liabilities (Net) 124 13 43 70 43
Total Non-Current Liabilities 8,774 8,661 8,564 12,576 5,285
Current Liabilities
Financial Liabilities 0 0 0 0 0
Borrowings 365 448 670 937 648
Lease Liabilities 488 411 365 215 0.0
Trade Payables 0 0 0 0 0
Total Outstanding Dues Of Micro Enterprises And Small
50 20 3 0 0.0
Enterprises
Total Outstanding Dues Of Creditors Other Than Micro
2,435 1,919 1,452 1,536 1,683
Enterprises And Small Enterprises
Other Financial Liabilities 1,404 936 1,428 2,654 2,557
Other Current Liabilities 755 785 626 305 337
Provisions 171 173 104 91 63
Income Tax Liabilities (Net) 25 5 4 22 12
Total Current Liabilities 5,693 4,698 4,653 5,758 5,300
Total Equity And Liabilities 23,160 22,195 20,356 22,532 16,015
19
www. h c g e l . c o m
 Historical Balance Sheet
Balance Sheet - Assets (in Rs. Mn.) Mar-23 Mar-22 Mar-21 Mar-20 Mar-19
Non-Current Assets
Property, Plant And Equipment 9,718 9,315 8,531 9,271 8,026
Capital Work in Progress 182 217 300 461 1,440
Rights-of-use Assets 3,813 4,045 4,114 5,776 0
Goodwill 1,812 1,813 963 1,093 1,093
Other Intangible Assets 187 298 215 320 96
Intangible Assets Under Development 30 206 268 469
Financial Assets 0 0 0 0
Investments 97 58 57 74 68
Loans Receivable 0 0 451 516 476
Other Financial Assets 543 546 168 222 196
Deferred Tax Assets (Net) 53 60 343 261 311
Income Tax Assets (Net) 574 459 426 818 307
Other Non-Current Assets 378 331 232 414 742
Total Non-Current Assets 17,357 17,172 16,007 19,494 13,222
Current Assets 0 0 0 0
Inventories 383 300 211 233 285
Financial Assets 0 0 0 0
Trade Receivables 3,025 2,175 1,866 1,857 1,646
Cash And Cash Equivalents 1,746 1,975 300 318 280
Bank Balances Other Than Cash And Cash
219 0 109 3 44
Equivalents
Loans 18 16 93 54 40
Other Financial Assets 74 341 1,546 275 211
Other Current Assets 339 217 225 300 288
Total Current Assets 5,803 5,024 4,350 3,038 2,793
Total Assets 23,160 22,195 20,356 22,532 16,015
20
www. h c g e l . c o m
 Historical Cash Flow Statement
Cash Flow Statement (in Rs. Mn) Mar-23 Mar-22 Mar-21 Mar-20 Mar-19

Net Profit Before Tax 449 878 -2,287 -1,193 -334

Adjustments For: Non - Cash Items / Other Investment Or Financial

2,753 1,666 3,619 2,988 2,463
Items

Operating Profit Before Working Capital Changes 3,201 2,543 1,333 1,795 2,130

Changes In Working Capital -459 -105 -507 -226 -774

Cash Generated From Operations 2,743 2,438 826 1,569 1,355

Direct Taxes Paid (Net Of Refund) -227 -237 380 -267 370

Net Cash From Operating Activities 2,516 2,201 1,205 1,301 985

Net Cash From Investing Activities -1,330 1,246 -1,711 -1,014 -2,382

Net Cash From Financing Activities -1,401 -1,549 1,123 -584 835

Net Increase/Decrease In Cash And Cash Equivalents -215 1,898 617 -297 -562

Add: Cash & Cash Equivalents At The Beginning Of The Period 1,927 29 -588 -291 271

Cash & Cash Equivalents At The End Of The Period 1,712 1,927 29 -588 -291

21
www. h c g e l . c o m
 THANK YOU
Company: HealthCare Global Enterprises Limited Investor Relation Advisors: Strategic Growth Advisors

CIN: L15200KA1998PLC023489 CIN: U74140MH2010PTC204285

For updates and specific queries, please visit Mr. Sagar Shroff / Mr. Ayush Haria
www.hcgoncology.com [email protected] / [email protected]
or feel free to contact [email protected] Tel: +91 98205 19303 / +91 98204 62966

© 2022 HealthCare Global Enterprises Limited., All Rights Reserved.

HCG Logo is trademark of HealthCare Global Enterprises Limited. In addition to Company data, data from market research agenci es, Stock Exchanges and industry publications has
been used for this presentation.
This material was used during an oral presentation; it is not a complete record of the discussion. This work may not be used, sold, transferred, adapted, abridged, copied or
reproduced in whole on or in part in any manner or form or in any media without the prior written consent. All product names and company names and logos mentioned herein are
the trademarks or registered trademarks of their respective owners.

www. h c g e l . c o m